Decision: Favourable

Decisions Table

Study Title:

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy Patients with Advanced Solid Tumours

  • NREC Code:

    22-NREC-CT-172

  • Decision:

    Favourable

  • Meeting Date:

    23/11/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Grainne O'Kane

  • PI Institution:

    St James' Hospital

  • Sponsor:

    Bold Therapeutics Inc

Scroll to Top